# reload+after+2024-01-22 17:32:36.335848
address1§Hulsterweg 82
city§Venlo
zip§5912 PL
country§Netherlands
phone§31 77 355 6600
fax§31 77 355 6658
website§https://www.qiagen.com
industry§Diagnostics & Research
sector§Healthcare
longBusinessSummary§QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
fullTimeEmployees§6000
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Thierry  Bernard', 'age': 58, 'title': 'CEO, MD & Member of Management Board', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 2675000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Roland  Sackers', 'age': 54, 'title': 'CFO, MD & Member of Management Board', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 1328000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Antonio  Santos', 'title': 'Senior VP & Head of Global Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John  Gilardi', 'title': 'Vice President of Corporate Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Stephany  Foster', 'age': 44, 'title': 'Senior VP & Head of Human Resources', 'yearBorn': 1979, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Thomas  Schweins', 'title': 'Senior Vice President of Life Science Business Area', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Thomas  Theuringer', 'title': 'Senior Director & Head of External Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jean-Pascal  Viola', 'title': 'Senior VP & Head of Molecular Diagnostics Business Area', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jonathan G. Sheldon Ph.D.', 'age': 51, 'title': 'Senior Vice President of Qiagen Digital Insights Business Area', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thomas  Neidert', 'title': 'Vice President of Global Treasury', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§1
boardRisk§3
compensationRisk§3
shareHolderRightsRisk§5
overallRisk§2
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.442
priceToSalesTrailing12Months§5.145554
currency§USD
dateShortInterest§1702598400
forwardEps§2.15
pegRatio§12.87
exchange§NYQ
quoteType§EQUITY
shortName§Qiagen N.V.
longName§Qiagen N.V.
firstTradeDateEpochUtc§835968600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§cd3854e5-bc64-3719-a489-cae381b2ddac
gmtOffSetMilliseconds§-18000000
targetHighPrice§60.0
targetLowPrice§42.5
targetMeanPrice§49.03
targetMedianPrice§48.0
recommendationMean§2.3
recommendationKey§buy
numberOfAnalystOpinions§15
quickRatio§2.599
earningsGrowth§-0.056
grossMargins§0.65980005
ebitdaMargins§0.27335
trailingPegRatio§2.2192
